Related Experiment Video
Updated: Aug 9, 2026
08:41
Modeling Chemotherapy Resistant Leukemia In Vitro
Published on: February 9, 2016
Summary
Cancer cells often develop resistance to chemotherapy. Novel strategies using nucleoside analogues and halogenated pyrimidines can enhance cancer treatment efficacy and imaging, even in resistant tumors.
Area of Science:
- Oncology
- Pharmacology
- Radiochemistry
Background:
- Chemotherapeutic agents face limited success due to cancer cell resistance.
- Some agents inhibit DNA synthesis in normal cells but not tumor cells, creating therapeutic opportunities.
- Halogenated pyrimidines show potential as radiosensitizers, but normal tissue uptake is a concern.
Purpose of the Study:
- To explore strategies for overcoming chemotherapy resistance in cancer.
- To investigate the use of nucleoside analogues and halogenated pyrimidines in cancer therapy.
- To assess the potential of radiolabeled pyrimidine analogues for tumor treatment and imaging.
Main Methods:
- Utilizing chemotherapeutic agents that selectively target cancer cells.
- Employing nucleoside analogues that are incorporated into cancer cell DNA.
- Investigating the co-administration of halogenated pyrimidines with agents that inhibit normal tissue uptake.
Main Results:
- Nucleoside analogues can be incorporated into cancer cells that continue DNA synthesis.
- Halogenated pyrimidines may sensitize cancers to irradiation when normal tissue uptake is inhibited.
- Radiolabeled pyrimidine analogues show promise for treating resistant tumors and for imaging.
Conclusions:
- Strategies involving nucleoside analogues can overcome chemotherapy resistance.
- Inhibiting normal tissue uptake of halogenated pyrimidines can enhance their therapeutic and imaging potential.
- Radiolabeled pyrimidine analogues offer a dual role in treating resistant cancers and in diagnostic imaging.
More Related Videos
08:59Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down
Published on: December 11, 2017
11:21Flow Cytometric Detection of Newly-formed Breast Cancer Stem Cell-like Cells After Apoptosis Reversal
Published on: January 26, 2019
Related Concept Videos
02:57Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
02:56Treatment Resistant Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
02:50Combination Therapies and Personalized Medicine
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
02:56Treatment Resistent Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
01:27Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists
5-HT3 receptor antagonists, such as dolasetron, granisetron (Kytril), ondansetron (Zofran), and palonosetron (Axoli), are crucial in managing chemotherapy-induced nausea and vomiting (CINV) and postoperative nausea. These drugs selectively block 5-HT3 receptors in the visceral vagal and spinal afferent nerves, chemoreceptor trigger zone, and the vomiting center. They have a rapid onset of action and can be given as a single dose before chemotherapy. Ondansetron and granisetron, in particular,...
01:29Chemotherapy-Induced Nausea and Vomiting: Dopamine Receptor Antagonists
Dopamine receptor antagonists, also known as antipsychotic agents, are critical in managing chemotherapy-induced vomiting. These antiemetic agents block dopamine receptors in the chemoreceptor trigger zone (CTZ), inhibiting signal transmission to the vomiting center. Antipsychotic agents encompass phenothiazines (PTZ), butyrophenones, benzamides, and thienobenzodiazepines (Zyprexa), which are utilized for their antiemetic and sedative properties.
Phenothiazines, such as prochlorperazine...
Phenothiazines, such as prochlorperazine...